New SEC Form D filing

Neuvivo, Inc., 2026-11-13

A new SEC Form D private-offering notice from Palo Alto, CA, a $9,500,000 filer-stated offering target in Biotech. The source filing is one click away.

What this filing says

Neuvivo, Inc. site↗ Verified via SEC Form D

Late clinical stage biopharmaceutical company developing NP001, an immune modulating treatment for ALS, with an FDA approval pathway underway.

Filed 6 days agoFiled to raise $9,500,000First money in 2026-10-30Raised so far $1,384,615HQ (as filed) Palo Alto, CASector Biotech web-verified against the company’s own siteStage (inferred) EarlyCall status Call-ready
Source linked the Form D on EDGAR↗Website verified neuvivo.com↗Named in the filing 5 executives & directors

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source